AJNR

Noninvasive Measurement of Brain Temperatureafter Stroke

Ronald J.T. Corbett, Phillip D. Purdy, Abbot R. Laptook, Curtis Chaney and Damian Garcia

Noninvasive Measurement of Brain Temperature after Stroke

Ronald J.T. Corbett, Phillip D. Purdy, Abbot R. Laptook, Curtis Chaney, and Damian Garcia

BACKGROUND AND PURPOSE: **Brain temperature may be an important factor governing the extent of neuronal injury associated with stroke. The goal of this study was to develop a noninvasive method for measuring brain temperature, both to characterize the extent to which temperature changes after stroke and to test protocols designed to reduce brain temperature. We used an animal model to test the ability of ^{1}H MR spectroscopy to measure temperature from infarcted brain tissue at 24 hours after insult.**

METHODS: **Unilateral permanent focal ischemia in the middle cerebral artery territory was induced in adult dogs by intravascular delivery of microfibrillar collagen. MR imaging performed at 24 hours after insult was used to guide the implantation of temperature probes into the basal ganglia infarct and into the same anatomic location on the contralateral side. Serial non-water-suppressed ^{1}H MR spectra were obtained from 1.3-cm^3 voxels using an echo time of 136 and 272 ms, alternately, from the infarcted and contralateral non-infarcted tissue during a period when brain temperature was raised and lowered by whole-body heating and cooling.**

RESULTS: **The chemical shift difference between the ^{1}H MR spectroscopy signal of water and *N*-acetylaspartate or water and trimethylamines was plotted against brain temperature for two voxel locations. The slope and intercept of the plots obtained for infarcted and non-infarcted brain were not significantly different ($P < .05$, *t* test), and there was no difference between the slope and intercept of plots made from data collected with an echo time of 136 or 272 ms.**

CONCLUSION: **The results of this study indicate that brain temperature can be measured from regions of brain containing infarcted tissue, at least up to 24 hours after ischemia. It should be possible to apply the ^{1}H MR spectroscopy method used in the present study to measure brain temperature after stroke.**

During the first week after stroke, there is a correlation between increased body temperature and decreased survival or neurologic recovery (1–3). Studies using animal models have shown that elevations in brain temperature of 1° to 2° C worsen neurologic and histologic indicators of ischemic brain damage (4, 5), and similar magnitude decreases during or after the insult diminish damage

(6–8). Several different types of protocols have been investigated in animal models to induce hypothermia, including whole-body cooling (6–8), localized head cooling (9, 10) and drug-induced cooling (11, 12). Positive results from these studies have provided the justification for clinical trials of whole-body cooling as a neuroprotective strategy after head injury (13) and raise the suggestion that similar approaches could be applied to reduce brain injury in patients after stroke (14), cardiac arrest (15), or neonatal hypoxic ischemia (16). It remains unclear, however, whether cooling protocols developed for and applied to animal models would be effective for reducing brain temperature in humans. The opportunity to measure brain temperature in humans directly has been limited to rare situations involving ventriculostomy, in which a temperature probe was implanted alongside each catheter (17–19). In such situations, the anatomic location of the temperature measurement site has been limited to the site where each catheter was implanted. It has not been possible to measure brain temperatures in different locations, such as the primary site of in-

jury, sites on the perimeter of the injury, or uninjured tissue.

We have shown that brain temperature can be measured using ^{1}H MR spectroscopy to quantify the MR frequency of water, which changes as a linear function of temperature (20–22). An attractive feature of this method is that temperature from virtually any region of the brain can be measured, allowing the possibility of examining the effectiveness of different protocols to reduce brain temperature in a variety of anatomic locations. A second feature is that the procedure is noninvasive, allowing direct brain temperature measurements in humans. A third feature the relationship between temperature and the chemical-shift difference of the MR signals corresponding to H_2O and a reference signal, such as N-acetylaspartate (NAA) and related compounds or trimethylamines (TMA), remain constant before, during, and after cerebral ischemia, as measured up to 90 minutes after ischemia. The possibility remains, however, that this relationship could change during a longer interval after stroke. There could be changes in the magnetic susceptibility experienced by H_2O relative to NAA and TMA within a voxel, with a consequent change in the relationship between the water and reference peaks. Ischemia may induce alterations in the concentrations of the chemical species, giving rise to the NAA and TMA MR peaks, resulting in a change in the chemical shift of the in vivo MR peak. Confirming that accurate temperature readings can be obtained from ischemically injured brain tissue after a longer post-insult period is important because stroke patients may not be sufficiently stable to allow transport to an MR facility until several hours after the initial insult.

The primary goal of this study was to test the hypothesis that the relationship between brain temperature and the chemical shift-difference between the MR spectroscopy peaks, which correspond to H_2O and NAA or H_2O and TMA, differs in normal non-infarcted brain versus infarcted brain tissue when measured at 24 hours after insult. A secondary goal was to assess these same relationships using an echo time (TE) of 272 ms for MR spectroscopy data collection, because this TE is commonly used for the collection of ^{1}H MR spectroscopy data from humans (23–26).

Methods

Surgical Preparation and Experimental Protocol

Surgical procedures and the experimental protocol were approved by the University of Texas Southwestern Medical Center Institutional Review Board for Animal Research and were in accordance with the *National Institutes for Health Guide for the Care and Use of Laboratory Animals*. The model of canine cerebral infarction has been described in detail previously (27, 28) and was followed with minor modifications as detailed below. On the day before the MR studies were initiated, adult mongrel dogs (n = 5) were anesthetized (thiamylal sodium, 20 mg/kg of body weight, IV administration), intubated, and ventilated with 2% to 5% isoflurane (balance air). The right

femoral artery in the groin was surgically exposed, and the tip of a transfemoral catheter was positioned 1 to 2 cm proximal to the bifurcation of the left common carotid artery, under fluoroscopic observation. To induce middle cerebral artery (MCA) occlusion, 30 to 50 mg of microfibrillar collagen (Avitene; Alcon Laboratories, Ft. Worth, TX) suspended in 0.5 mL of normal saline was introduced into the catheter and flushed with saline. The catheter was removed, the surgical site sutured, and the ventilation mixture switched to 100% air. The animal was allowed to awaken, was extubated, and was returned to a holding room until the next day. Analgesia (0.02 mg/kg buprenorphine, intramuscular administration) and penicillin (600,000 units, intramuscular administration) were administered to the animal, and the animal was transported to a holding area and observed periodically during the ensuing ~18 hours. The next morning, the animal was transported to the MR facility and a neurologic evaluation was performed using a standardized categorical rating scale, described in detail previously (29), to evaluate motor function (no deficit = 1, hemiparetic but able to walk = 2, stands only with assistance = 3, hemiplegia and unable to stand = 4), consciousness (normal = 1, mildly reduced = 2, severely reduced = 3, comatose = 4), head turning (absent = 0, posturing and turns toward side of infarct = 1, comatose = 1), circling (absent = 0, present = 1, does not walk = 1), and hemianopsia (absent = 0, present = 1, unable to test because of reduced consciousness = 1). According to this scale, a normal animal would have a composite score of 2 and an animal with the most severe deficits would have a score of 11. Next, the animal was anesthetized, intubated, and ventilated as described above. A second dose of buprenorphine was administered, and pancuronium bromide (0.3 mg/kg per hour, IV administration) was given for muscle relaxation to ensure no movement during MR measurements. A femoral arterial catheter was used to monitor heart rate and blood pressure and to draw blood for PCO_2, PO_2, and pH. The scalp was retracted, and two burr holes were made in the skull for subsequent implantation of temperature probes into the infarcted and contralateral hemispheres.

On the morning of the study, three fiber optic temperature sensors (model MIA sensors and a model 750 monitor; Luxtron, Mountain View, CA) were calibrated at room temperature, relative to a type T copper/constantan thermocouple and thermometer (Cole-Palmer, Chicago, IL). At the end of each study, the calibration of the three sensors was retested; the average change in the readings compared with the initial calibration was $0.04 \pm 0.20°C$. After transporting the animal to the magnet, it was wrapped in a thermal blanket with thermostatically controlled circulating water passing through it, and one temperature sensor was inserted to measure rectal temperature. The MR coil was placed around the head, and the animal was placed in the magnet for MR imaging to identify infarcted regions of brain for subsequent ^{1}H MR spectroscopy measurements. The animal was then removed from the magnet, and with the MR coil left in place, two temperature sensors were implanted 1.5 to 2.5 cm into the brain. The exact depth and location of probe implantation was guided by the MR images, with one sensor implanted into the region of infarct and the other sensor implanted contralateral to the infarct in the analogous anatomic location. The animal was then returned to the magnet and reimaged, and voxels were selected for MR spectroscopy measurements. During the MR imaging and temperature sensor implantation, the rectal temperature was maintained at 39°C, and the ventilation rate and tidal volume were adjusted to maintain arterial blood PO_2 and PCO_2 readings in the range of 100 to 200 and 30 to 45 mmHg, respectively. During the next 3 to 4 hours, the temperature of the animal was gradually increased or decreased by passing warm or cool water through the blanket surrounding the animal, with concurrent recordings of rectal and brain temperature from the sensors and ^{1}H MR spectroscopy data collection from the infarcted and non-infarcted contralateral brain regions. Arterial

blood pH, PO_2, and PCO_2 were measured every 60 minutes, and heart rate and mean arterial blood pressure were recorded every 30 minutes. At the end of the MR study, the animal was euthanized by pentobarbital overdose (120 mg pentobarbital/ kg, IV administration). To confirm the location of the infarct measured by MR imaging and MR spectroscopy, the brain was removed and 5-mm-thick sections obtained from the coronal plane were stained with 2,3,5-triphenyl, 2-H tetrazolium chloride (TTC) as described previously (30). Previous studies have shown the concordance between infarct locations identified by the absence of TTC staining and conventional histologic staining methods for this and similar models (31, 32).

MR Data Collection and Data Analysis

All MR experiments were performed using a 1.5-T Philips NT system (Philips Medical Systems, Shelton, CT) and the manufacturer's knee imaging coil as described previously (22). Imaging consisted of a modified rapid acquisition with relaxation enhancement, turbo spin-echo pulse sequence to provide T2-weighted images ($2.0 \times 0.6 \times 0.7$-mm resolution) in the sagittal and coronal (perpendicular to the corpus callosum) planes (10 and 20 sections, respectively). These images were used to guide the selection of two 1.3-cm^3 voxels for ^1H MR spectroscopy measurements from the infarcted and non-infarcted cerebral hemispheres, respectively. Non-H_2O-suppressed ^1H MR spectra were obtained using a point-resolved spectroscopy sequence with a sweep width of 750 Hz and 1024 data points per spectrum. The delay time between excitation pulses was 2.7 seconds, and the TE was 136 or 272 ms. After four dummy images were obtained to establish partial saturation, 64 or 128 free induction decays were accumulated for each spectrum in 3 or 6 minutes, respectively. The accumulated ^1H free induction decays were processed by baseline correction to remove direct current offsets, 2 Hz exponential apodization, zero filling to 16,384 data points (final digital resolution $= 0.0007$ ppm/ data point), Fourier transformation, and manual zero-order phasing to provide the maximum positive intensity for both the H_2O and NAA nuclear MR peaks. The chemical-shift scales of all spectra were calibrated with respect to the location of the NAA ^1H MR peak set to 2.02 ppm. The exact chemical shifts corresponding to the H_2O, TMA, and NAA MR peaks were determined using the "single peak analysis" software that is routinely supplied with the spectrometry system (versions 5.1 and 5.2 operating systems). Using linear regression analysis, a total of 67 MR spectra from the five dogs were collected to investigate the relationship between chemical shift and brain temperature: 35 spectra (contralateral, n = 15; infarcted, n = 20) using a TE of 136 ms, and 32 spectra (contralateral, n = 16; infarcted, n = 20) using a TE of 272 ms. For data collected at either TE, brain temperature measured from the implanted probes was plotted versus the chemical-shift (δ) difference between the ^1H nuclear MR frequencies of water and NAA (Δ $\delta H_2O - \delta NAA$) and between water and TMA (Δ $\delta H_2O - \delta TMA$), and statistical tests were performed to test for different slopes and elevations (33). All data are presented as a mean $\pm$ SD for the five animals studied unless otherwise noted.

Results

The neurologic assessment made at 20 to 22 hours after the MCA embolization revealed abnormalities in four of the five animals, with the composite neurologic scores ranging from 6 to 10. In the four abnormal animals, there were deficits in motor function (score range, $2-4$), consciousness (score range, $2-3$), head turning (score, 1), and circling (score, 1), and in three animals, hemianopsia (score, 1) was present. The neurologic status of


FIG 1. ^1H MR image of canine brain. A T2-weighted coronal image, obtained 24 hours after MCA embolization, shows hyperintense signal from the basal ganglia. The *box* shows the location of the voxel used for ^1H MR spectroscopy data collection from the infarct; the same-sized voxel was collected from the analogous anatomic region contralateral to the infarct.

a fifth animal was normal, and subsequent MR imaging measurements, TTC staining, and examination of the brain of this animal revealed no evidence of infarction. As observed previously, in approximately 10% of animals, the injected collagen apparently occludes the external carotid artery rather than the MCA territory and does not result in ischemic injury (29). For this fifth animal, a single temperature probe was implanted into the same vicinity of brain as for other animals, and the resulting data collected during the protocol were combined with the data collected from the contralateral regions for the other four animals.

Arterial blood pH (7.21 ± 0.04), PO_2 (163 ± 29 mmHg), PCO_2 (33 ± 3 mmHg), heart rate (134 ± 20 bpm), and mean arterial blood pressure (120 ± 18 mmHg), recorded at the beginning of MR data collection, indicated that all of the animals were physiologically stable. These readings remained constant throughout the protocol. The MR images obtained from the four animals with neurologic deficits revealed abnormalities in the cerebral hemisphere ipsilateral to the collagen injection (Fig 1). In all four animals, T2-weighted MR images revealed the presence of unilateral hyperintense signal in the MCA territory, comprising the basal ganglia of one hemisphere. In one animal, there was also extensive hyperintensity present in the cerebral cortex of the same hemisphere (not shown). Subsequent removal and TTC staining of the brains of these animals at the end of the protocol revealed decreased uptake of TTC in the same regions showing hyperintense signal in the MR images and confirmed the presence of unilateral nonhemorrhagic infarcts.

The average temperatures recorded from contralateral brain tissue and rectum at the start of ^1H

FIG 2. Representative ¹H MR spectra from infarcted and contralateral non-infarcted brain tissue using TEs of 136 ms and 272 ms (data from the same animal as that depicted in Fig 1). The MR signals corresponding to H₂O, TMA, creatine plus phosphocreatine, NAA, and related compounds, and lactate are identified. A five-times larger vertical scaling factor was used for the data collected using a TE of 272 ms, compared with the data collected using a TE of 136 ms.

A, ¹H MR spectra of infarcted brain tissue (TE, 136).
B, ¹H MR spectra of non-infarcted brain tissue (TE, 136).
C, ¹H MR spectra of infarcted brain tissue (TE, 272).
*D,* ¹H MR spectra of non-infarcted brain tissue (TE, 272).

FIG 3. Comparison of the relationship between brain temperature measured from sensors implanted into the infarcted and contralateral non-infarcted tissue versus the chemical-shift differences between H₂O and NAA (*left*) and between H₂O and TMA (*right*). Only data collected using a TE of 136 ms are depicted. The *lines* show the best fit by linear regression analysis. There was no significant difference in the slope or elevation of the data collected from the infarct compared with the non-infarcted tissue.

MR spectroscopy data collection were 39.1 ± 1.1 and 38.9 ± 1.2°C, respectively. Temperatures recorded throughout the protocol indicated a systematic difference between the cerebral temperatures recorded from the two implanted temperature probes for three of the four animals with infarcts. In one animal, the average difference (ie, infarct minus contralateral) was 0.07 ± 0.09°C (paired *t* test, *P* = .01), whereas in two animals, the average difference was −0.39 ± 0.15 and −0.40 ± 0.19°C (*P* < .0005).

Non-water-suppressed ¹H MR spectroscopy data were collected from a voxel centered on the infarct located in the basal ganglia and from the same-sized volume contralateral to the infarcted hemisphere (Fig 2). MR spectroscopy peaks corresponding to H₂O, TMA, creatine (Cr) plus phosphocreatine, and NAA were visible in both the infarcted and non-infarcted tissue, although the signal from NAA relative to creatine and TMA appeared to be approximately 20% to 50% lower in the former compared with the latter tissue. A peak located at 1.3 ppm, assigned to lactate, was also present in MR spectroscopy spectra collected using a TE of 272 from the infarct (Fig 2C).

For ¹H MR spectroscopy data collected using a TE of 136, there was a significant linear relationship (*P* < 0.05) between the chemical shift differences Δ δH_2O − δNAA or Δ δH_2O − δTMA versus brain temperature (Fig 3). A comparison of the best-fit linear regression lines revealed no significant difference between the slope and elevations for noninfarcted compared with infarcted tissue, for both Δ δH_2O − δNAA and Δ δH_2O − δTMA versus brain temperature relationships (*t* test, *P* > .05). A similar comparison using data collected with a TE of 272 ms yielded the same findings. A com-

parison of combined data (infarcted and noninfarcted) revealed no difference in the slope or intercept of data collected using a TE of 136 ms versus a TE of 272 ms. The best fit by linear regression for combined data (ie, TE 136 and 272 plus non-infarcted and infarcted) gives: T_{NAA} = −82.33 ± 6.58 (Δ δH_2O − δNAA) + 255.94 ± 1.30 (r^2 = 0.71) and T_{TMA} = −70.11 ± 6.06 (Δ δH_2O − δTMA) + 140.03 ± 1.31 (r^2 = 0.69).

Discussion

The use of ¹H MR spectroscopy to measure brain temperature is contingent on identifying and measuring the location of at least one of the two reference peaks, NAA or TMA. One of our early concerns was that there would be insufficient signal intensities from NAA to be used as a chemical shift reference, because NAA decreases during the first several hours after stroke (24–26, 32, 34). Although we observed lower relative NAA signal intensities for the voxel centered on the infarct, the signal from NAA was still sufficient to make peak assignments and quantify the chemical shift unambiguously. It is conceivable that the signal from NAA measured from this voxel was derived from peripheral noninfarcted tissue because of partial volume averaging. We could have mitigated partial volume averaging effects somewhat by using the MR instrument's minimum allowed voxel size (1 cm³). This, however, would have required imaging times that were approximately 4.8 times longer and would have prevented our goal of collecting MR spectroscopy data over a range of different brain temperatures, but with constant temperatures during each imaging session, within our allotted time on the MR instrument. Alternatively, attempting to create a larger volume of infarct by injecting a greater volume of collagen would substantially de-

crease the chances of survival for 24 hours (27, 28). The temperature-chemical-shift difference relationship examined using TMA as the chemical shift reference should not be as subject to the problem of partial volume averaging; previous studies have shown that TMA either remains constant or increases after stroke (24, 34). The fact that similar slopes and intercepts were obtained from infarcted and noninfarcted tissue when using NAA or TMA as the reference peak supports the conclusion that the relationship between temperature- and chemical-shift difference is unaffected by infarction.

It has been shown that the magnetic susceptibility effects on muscle (35) and brain (36, 37) can affect the determination of temperature using phase-contrast MR imaging, which, as does the present method, assumes linear temperature-dependent changes in the MR frequency of water. The accuracy of the present method should not be impaired by magnetic susceptibility as long as the water and reference peaks are equally effected. The concurrence of slopes and intercepts for infarcted and noninfarcted tissues obtained in the present study implies that changes in magnetic susceptibility in brain tissue after stroke, if any, were not sufficient to affect the temperature-chemical shift difference relationship. It is worth noting that the four abnormal animals studied were judged to have nonhemorrhagic embolic strokes in the MCA territory. Although not addressed herein, it is possible that a hemorrhagic stroke could generate significantly greater magnetic susceptibility effects, which could impact the ability of the MR spectroscopy method to measure temperature to a greater degree than that observed in this study. It may be possible to use our canine model to examine the ability of ^{1}H MR spectroscopy to measure temperature in hemorrhagic infarcts, because this model gives an increasing proportion of hemorrhagic infarcts as the interval between the MCA embolization increases beyond 24 hours (27, 29).

The in vivo TMA ^{1}H MR peak in the dog brain likely derives the bulk of its signal from glycerophosphocholine, with minor contributions from phosphocholine and choline, whereas the NAA peak derives its signal primarily from NAA, with minor contributions from N-acetylaspartylglutamate, glutamate, and acetate (38). It is conceivable that the relative contribution of these compounds to the in vivo signal could change in infarcted compared with noninfarcted tissue, causing a change in the location of the NAA and TMA reference peaks relative to water. This, in turn, would cause a systematic error in the calculation of brain temperature from measurements of Δ $\delta H_2O - \delta NAA$ or Δ $\delta H_2O - \delta TMA$, if one were relying on calibration data obtained from noninfarcted tissue. The results of this study, however, imply that the chemical species comprising the in vivo NAA and TMA signal must not change sufficiently to produce a change in the chemical shift in the ^{1}H MR peak, because there was no difference in the slope and intercept

of the temperature-chemical shift difference relationship measured for noninfarcted and infarcted tissue. A potential exception to this conclusion may occur in the use of shorter TE (ie, TE < 136) for the collection of ^{1}H MR spectroscopy data, because the relative contributions from other species, including macromolecules, is increased under these conditions (34, 39, 40).

Another factor that could limit the application of ^{1}H MR spectroscopy temperature measurements in a clinical setting is that the variation in temperature readings suggests an accuracy of approximately $\pm$ 1°C, similar to that of our earlier studies (21, 22). As discussed previously, sources of error could include temperature variations within the voxel or during the MR spectroscopy data collection period, the digital resolution of data collection and phasing of spectra, and the temperature sensors themselves as well as the thermocouple used in the calibration (22). Because of these errors, it is difficult to draw firm conclusions regarding brain temperature variations during stroke or modulation of brain temperature responding to a cooling protocol from the study of individual patients when the change in brain temperature is in the range of 1° to 2°C.

Another concern is the reproducibility of measuring temperature changes between multiple MR sessions. Although not addressed directly by the present study, there are two lines of evidence to suggest that this is not a problem. First, data collected from different animals during a period of several weeks all follow the same linear relationship (Fig 3). Similar results were obtained in studies of swine brain (21, 22). Second, in a previous study of human subjects, there was no significant difference in brain temperature measured in two successive MR sessions, with and without localized head surface cooling (41). Therefore, temperature measures using this technique are fairly robust and independent of fluctuations in the MR system. The reason for this is that each MR spectrum has NAA or TMA as its own internal chemical shift reference.

Despite these reservations, we think that the ^{1}H MR spectroscopy method described herein could help resolve a number of issues concerning brain temperature monitoring, manipulation, and regulation after stroke or other cerebral injuries. It remains unclear whether brain temperature is selectively regulated during fever associated with stroke, similar to that proposed in normal humans during heat stress (42). Alternatively, infarcted brain tissue temperature may be decreased substantially, similar to that reported as occurring in humans experiencing cerebral death (43). It is conceivable that significant temperature gradients could exist within the brain after stroke and that these gradients change as a function of evolving brain damage (19). A related issue is whether changes in core body temperature or temperature measured from other locations (ie, tympanum or oral) provide an accurate indication of changes in brain temperature

after stroke. Finally, the efficiency of various protocols designed to reduce brain temperature therapeutically could be tested directly in human volunteers or in patients, as recently illustrated (41).

Conclusion

The primary finding of this study is that the relationship between temperature and the chemical-shift difference between water and the reference peaks of NAA or TMA (ie, $\Delta \delta H_2O - \delta NAA$ or $\Delta \delta H_2O - \delta TMA$) do not differ between infarcted and non-infarcted brain tissue. Because these experiments were collected using a clinical MR imaging/MR spectroscopy system, the methodology is directly applicable to the study of human participants. Specifically, the results suggest that ^{1}H MR spectroscopy could be used to obtain accurate measurements of brain temperature in humans after stroke for periods of up to at least 24 hours after insult. A second finding is that the relationship between brain temperature and the chemical-shift difference is the same regardless of whether a TE of 136 ms or 272 ms was used for ^{1}H MR spectroscopy data collection.

References

1. Castillo J, Martinez F, Leira R, Prieto R, Lema M, Noya M. **Mortality and morbidity of acute cerebral infarction related to temperature and basal analytic parameters.** *Cerebrovasc Dis* 1994;4:66–71
2. Azzimondi G, Bassein L, Nonino F, et al. **Fever in acute stroke worsens prognosis: a prospective study.** *Stroke* 1995;26:2040–2043
3. Reith J, Jorgensen H, Pedersen P, et al. **Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome.** *Lancet* 1996;347:422–425
4. Kim Y, Busto R, Dietrich D, Kraydieh S, Ginsburg M. **Delayed postischemic hyperthermia in awake rats worsens the histopathologic outcome of transient focal cerebral ischemia.** *Stroke* 1996;27:2274–2281
5. Wass TC, Lanier WL, Hofer RE, Scheithauer BW, Andrews AG. **Temperature changes of >1°C alter functional neurologic outcome and histopathology in a canine model of complete cerebral ischemia.** *Anesthesiology* 1995;83:325–335
6. Busto R, Dietrich W, Globus M-T, Valdes I, Scheinburg P, Ginsburg M. **Small differences in intraischemic brain temperature critically determine the extent of ischemic neuronal injury.** *J Cereb Blood Flow Metab* 1987;7:729–738
7. Zhang R-L, Chopp M, Chen H, Garcia J, Zhang Z. **Postischemic (1 hour) hypothermia significantly reduces ischemic cell damage in rats subjected to 2 hours of middle cerebral artery occlusion.** *Stroke* 1993;24:1235–1240
8. Barone F, Feuerstein G, White R. **Brain cooling during transient focal ischemia provides complete neuroprotection.** *Neurosci Biobehav Rev* 1997;21:31–44
9. Horn M, Schlote W, Henrich H. **Global cerebral ischemia and subsequent selective hypothermia.** *Acta Neuropatho (Berl)* 1991;81:443–449
10. Gelman B, Schlein C, Lohe A, Kuluz J. **Selective brain cooling in infant piglets after cardiac arrest and resuscitation.** *Crit Care Med* 1996;24:1009–1017
11. Hall E, Andrus P, Pazara K. **Protective efficacy of a hypothermic pharmacological agent in gerbil forebrain ischemia.** *Stroke* 1993;24:711–715
12. Nurse S, Corbett D. **Neuroprotection following several days of mild drug-induced hypothermia.** *J Cereb Blood Flow Metab* 1996;16:474–480
13. Marion D, Penrod L, Kelsey S, et al. **Treatment of traumatic brain injury with moderate hypothermia.** *N Engl J Med* 1997;336:540–546
14. Ginsburg M, Busto R. **Combating hyperthermia in acute stroke: a significant clinical concern.** *Stroke* 1998;29:529–534
15. Safar P, Klain M, Tisherman S. **Selective brain cooling after cardiac arrest.** *Crit Care Med* 1996;24:911–914
16. Wyatt J, Thoresen M. **Hypothermia treatment and the newborn.** *Pediatrics* 1997;100:1028–1029
17. Mellergard P. **Changes in human intracerebral temperature in response to different methods of brain cooling.** *Neurosurgery* 1992;31:671–677
18. Ginsberg MD. **Therapeutic modulation of brain temperature: relevance to ischemic brain injury.** *Cerebrovasc Brain Metab Rev* 1992;4:189–225
19. Schwab S, Spranger M, Aschoff A, Steiner T, Hacke W. **Brain temperature monitoring and modulation in patients with severe MCA infraction.** *Neurology* 1997;48:762–767
20. Corbett R, Tollefsbol G, Laptook A. **Measurement of brain temperature in vivo using ^{1}H NMR spectroscopy.** *Soc Mag Res* 1994;1:516
21. Corbett RJT, Laptook AR, Tollefsbol G, Kim B. **Validation of a noninvasive method to measure brain temperature in vivo using ^{1}H NMR spectroscopy.** *J Neurochem* 1995;64:1224–1230
22. Corbett R, Laptook A, Weatherall P. **Noninvasive measurements of human brain temperature using volume-localized proton magnetic resonance spectroscopy.** *J Cereb Blood Flow Metab* 1997;17:363–369
23. Barker P, Gillard J, van Zijl P, et al. **Acute stroke: evaluation with serial MR spectroscopic imaging.** *Radiology* 1994;192:723–732
24. Gideon P, Henriksen O, Sperling B, et al. **Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke.** *Stroke* 1992;23:1566–1572
25. Graham G, Blamire A, Rothman D, et al. **Temporal variation of cerebral metabolites after human stroke: a proton magnetic resonance spectroscopy study.** *Stroke* 1993;24:1891–1896
26. Houkin K, Kamada K, Kamiyama H, Iwasaki Y, Abe H, Kashiwaba T. **Longitudinal changes in proton magnetic resonance spectroscopy in cerebral infarction.** *Stroke* 1993;24:1316–1321
27. Purdy P, Devous M, White C, Batjer H, Samson D, Hodges K. **Reversible middle cerebral artery embolism in dogs without intracranial surgery.** *Stroke* 1989;20:1368–1376
28. Purdy P, White C, Batjer H, Brewer K, Hodges K, Samson D. **Intracarotid hydroxyethyl methacrylate solution causing stroke in dogs.** *J Neurosurg* 1990;73:756–759
29. Purdy P, Devous M, Batjer H, White C, Meyer Y, Samson D. **Microfibrillar collagen model of canine cerebral infarction.** *Stroke* 1989;20:1361–1367
30. Purdy P, Devous M, Batjer H, White C, Meyer Y, Samson D. **Calcium 45 autoradiography and dual isotope single-photon emission CT in a canine model of cerebral ischemia and middle cerebral artery occlusion.** *AJNR Am J Neuroradiol* 1996;17:1161–1170
31. Bederson J, Pitts L, Germano S. **Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats.** *Stroke* 1986;17:1304–1308
32. Monsein L, Mathews V, Barker P, et al. **Irreversible regional cerebral ischemia: serial MR imaging and proton MR spectroscopy in a nonhuman primate model.** *AJNR Am J Neuroradiol* 1993;14:963–970
33. Zar J. *Biostatistical Analysis.* Englewood Cliffs: Prentice-Hall Inc.; 1984:292
34. Saunders D, Howe F, van den Boogaart A, Mclean M, Griffiths J, Brown M. **Continuing ischemic damage after acute middle cerebral artery infarction in humans demonstrated by short-echo proton spectroscopy.** *Stroke* 1995;26:1007–1013
35. Young I, Hajnal J, Roberts I, et al. **An evaluation of the effects of susceptibility changes on the water chemical shift method of temperature measurement in human peripheral muscle.** *Magn Reson Med* 1996;36:366–374
36. Kuroda K, Abe K, Tsutsumi S, Ishihara Y, Suzuki Y, Sata K. **Water proton magnetic resonance spectroscopic imaging.** *Biomed Therm* 1993;13:43–62
37. Kuroda K, Somatani N, Suzuki Y, Ishihara Y, Okamoto K, Suzuki Y. **Temperature mapping using water proton chemical shift.** *Soc Magn Reson* 1994;3:1569
38. Barker P, Breiter S, Soher B, et al. **Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations.** *Magn Reson Med* 1994;32:157–163

39. Graham G. **Brain macromolecules: in vivo measurement by proton magnetic resonance spectroscopy.** *Neuroscientist* 1996;2:309–312
40. Van Zijl P, Barker P. **Magnetic resonance spectroscopy and spectroscopic imaging for the study of brain metabolism.** *Ann N Y Acad Sci* 1997;820:75–96
41. Corbett R, Laptook A. **Failure of localized head cooling to reduce brain temperature in humans.** *Neuroreport* 1998;9:2721–2725
42. Cabnac M. **Selective brain cooling in humans: "fancy" or fact?** *FASEB J* 1993;7:1143–1147
43. Orita T, Izumihara A, Tsurutani T, Kajiwara K. **Brain temperature before and after brain death.** *Neurol Res* 1995;17:443–444.